Kennedy Advisers Consider Major Revisions to Childhood Vaccination Schedule
Advisers to Health Secretary Robert F. Kennedy Jr. are considering major revisions to the childhood vaccination schedule, including delaying or potentially removing the routine hepatitis B shot given at birth, The New York Times' Apoorva Mandavilli reports. Although not legally binding, their decisions could significantly influence insurance coverage and public health guidelines, with members also expected to debate vaccine ingredients and the use of combination shots, Mandavilli writes. Publicly traded companies that could be impacted include Moderna (MRNA), Pfizer (PFE), BioNTech (BNTX), Novavax (NVAX), AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY), and Sanofi (SNY).
Discover Tomorrow's Bullish Stocks Today
Analyst Views on AZN
About AZN
About the author

AstraZeneca Announces $15B Investment in China to Expand Operations
- Major Investment Plan: AstraZeneca has announced a $15 billion investment in China by 2030 to expand its drug manufacturing and R&D capabilities, marking the next phase of the company's development in China, which is expected to significantly enhance its cell therapy and radioconjugates capabilities.
- Strategic Market Positioning: China has become AstraZeneca's second-largest market, and this investment will further solidify its strategic hub status in global innovation, particularly with two global R&D centers in Beijing and Shanghai that have led 20 global clinical trials to date.
- Enhancing Public Health Contribution: CEO Pascal Soriot stated that this investment will strengthen AstraZeneca's contribution to high-quality development in China, especially in breakthrough treatment areas like cell therapy, bringing next-generation modalities to patients.
- Manufacturing and R&D Capacity Boost: This investment will not only increase the capacity of four manufacturing sites but also drive commercial operations across five regional hubs, further enhancing the company's competitiveness and influence in the Chinese market.

AstraZeneca Announces $15 Billion Investment in China
- Investment Scale: AstraZeneca has announced a $15 billion investment in China by 2030 to expand its medicines manufacturing and R&D capabilities, further solidifying its market position in the region.
- UK-China Collaboration: This investment was announced during the UK Prime Minister's visit to China, expected to strengthen collaboration in healthcare innovation and promote the development of life sciences ecosystems in both countries.
- Job Creation: AstraZeneca's investment will grow its highly skilled workforce in China to over 20,000 and create thousands of additional jobs across the healthcare ecosystem, supporting job growth in the UK.
- Enhanced R&D Capabilities: The investment will significantly enhance AstraZeneca's capabilities in cell therapy and radioconjugates, leveraging its global strategic R&D centers in Beijing and Shanghai, which collaborate with over 500 clinical hospitals to advance global clinical trials.









